Journal of Pharmaceutical Investigation Reaches Q1 Standing With 5.5 Impact Factor

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical sciences and drug development research, has secured a prominent position in the global scientific publishing landscape, achieving an impact factor of 5.5 in 2022 and earning a Q1 ranking of 48 out of 278 journals in the Pharmacology and Pharmacy category. The standing reflects the journal’s growing influence in a field that sits at the crossroads of chemistry, biology, medicine and regulatory science, and it underscores how abstracting and indexing services have become the invisible infrastructure that determines which research reaches the widest audience and which journals rise to the top of their disciplines.

Abstracting and indexing, often abbreviated as A&I, is the process by which bibliographic databases catalog scholarly articles, capturing their titles, authors, abstracts, keywords and citations in structured records that can be searched, sorted and analyzed at scale. For researchers, these databases are the primary discovery tools of modern science: a paper that is not indexed in the major services is effectively invisible to most of the global research community, no matter how rigorous its methods or how significant its findings. For journals, inclusion in prestigious indexes is both a badge of quality and a practical necessity, because libraries, funders and tenure committees routinely evaluate publications based on where they are indexed and what citation metrics those indexes generate.

The Journal of Pharmaceutical Investigation has been abstracted and indexed in the Science Citation Index Expanded, commonly known as SciSearch, since 2021. The Science Citation Index Expanded is maintained by Clarivate as part of the Web of Science platform, one of the most authoritative citation databases in the world. It traces its lineage to the original Science Citation Index created by Eugene Garfield in the 1960s, a pioneering effort to map the flow of ideas through the scientific literature by tracking which papers cite which. That citation network remains the foundation of modern bibliometrics, and inclusion in the expanded index signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial content, international diversity and citation behavior.

Once a journal is indexed in the Science Citation Index Expanded, it becomes eligible for the Journal Impact Factor, the single most widely cited metric in scholarly publishing. The impact factor is calculated by dividing the number of citations received in a given year by items published in the journal during the two preceding years. A journal’s 2022 impact factor of 5.5 therefore means that, on average, articles published in 2020 and 2021 were cited 5.5 times each during 2022. While the metric has well-documented limitations, it remains a shorthand that researchers, institutions and publishers watch closely, and movement in the rankings can shape manuscript submission patterns, editorial strategies and even national research assessment frameworks.

A ranking of 48 out of 278 journals places the Journal of Pharmaceutical Investigation in the first quartile, or Q1, of the Pharmacology and Pharmacy category, meaning it sits among the top 25 percent of titles in its field. Quartile rankings are derived by ordering journals within a category by impact factor and dividing them into four equal bands. Q1 status is particularly meaningful in pharmacology, one of the most competitive categories in the Web of Science, where established titles with decades of history and enormous submission volumes compete for citation attention. For a journal to reach and hold a Q1 position, its published work must not only meet high editorial standards but also resonate with a broad community of researchers who choose to cite it in their own studies.

The journal’s subject matter helps explain that resonance. Pharmaceutical investigation encompasses the entire lifecycle of a drug, from early discovery and formulation science through pharmacokinetics, pharmacodynamics, clinical evaluation, manufacturing quality and post-marketing surveillance. Research in this space is inherently translational, connecting laboratory findings to therapeutic outcomes, and it draws citations from a wide range of adjacent disciplines, including biotechnology, nanomedicine, regulatory affairs and clinical pharmacy. Journals that publish work spanning this breadth tend to accumulate citations from many communities, which strengthens their bibliometric performance and, in a self-reinforcing loop, attracts further high-quality submissions from authors seeking visibility.

The timing of the journal’s SciSearch inclusion in 2021 and its subsequent impact factor performance illustrates a broader dynamic in scholarly publishing. New or newly indexed journals typically need two full publication cycles before their first official impact factor can be calculated, because the metric depends on a two-year citation window. The years immediately following indexing are therefore critical: editors work to commission review articles, which are disproportionately cited, and to attract original research from prominent groups, knowing that early citation performance will set the trajectory of the journal’s metrics for years to come. Achieving a 5.5 impact factor within a short period of entering the index suggests that the journal’s editorial strategy and its community of contributors have aligned effectively with the citation patterns of contemporary pharmaceutical research.

Behind the headline numbers lies an elaborate ecosystem of data infrastructure. When an article is published, its metadata are transmitted to indexing services, where they are normalized against standards for author names, affiliations, funding information and references. Citation links are then resolved and aggregated, feeding not only the impact factor but also a family of related indicators, including the five-year impact factor, the immediacy index, the cited half-life and the eigenfactor, each of which captures a different dimension of a journal’s scholarly footprint. Databases also power literature search engines, reference managers and systematic review workflows, meaning that indexing quality directly affects how efficiently science itself proceeds. Errors or gaps in indexing can delay discoveries, skew bibliometric analyses and misrepresent the provenance of ideas.

For the pharmaceutical sciences specifically, robust indexing carries practical stakes beyond prestige. Systematic reviews and meta-analyses, which underpin clinical guidelines and regulatory decisions, depend on comprehensive database coverage to identify all relevant evidence. Pharmacovigilance researchers tracking adverse events, formulation scientists surveying delivery technologies and health economists assessing drug value all rely on indexed literature to build complete pictures of the evidence base. A journal’s presence in the Science Citation Index Expanded therefore contributes to the reliability of the evidence synthesis on which drug safety and efficacy decisions ultimately rest, a responsibility that extends well beyond the publishing world into patient care.

The Journal of Pharmaceutical Investigation’s Q1 standing in 2022 is a snapshot of a competitive and rapidly evolving field, and maintaining that position will require continued editorial rigor as publishing itself changes. Preprint servers, open access mandates, alternative metrics and new assessment frameworks such as the Declaration on Research Assessment are reshaping how scholarly value is measured, and citation-based indicators are increasingly scrutinized for the ways they can be gamed or misapplied. Yet for now, the combination of SciSearch indexing and a 5.5 impact factor confirms the journal’s place among the leading venues for pharmaceutical research, offering authors a platform with global discoverability and offering readers a curated window into the science that moves molecules from the bench to the bedside.

Subject of Research: The indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor and Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, abstracting and indexing, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, pharmaceutical sciences, bibliometrics, Clarivate